## Heinz H Coenen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4220182/publications.pdf

Version: 2024-02-01

66343 60623 7,101 137 42 81 citations h-index g-index papers 140 140 140 6307 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain, 2005, 128, 678-687.	7.6	537
2	Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release. Journal of Neuroscience, 2008, 28, 14311-14319.	<b>3.</b> 6	426
3	O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nuclear Medicine and Biology, 2006, 33, 287-294.	0.6	317
4	Combined MRI–PET dissects dynamic changes in plant structures and functions. Plant Journal, 2009, 59, 634-644.	5.7	268
5	Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Annals of Neurology, 2003, 54, 479-487.	5 <b>.</b> 3	235
6	Nucleophilic18F-Fluorination of Heteroaromatic Iodonium Salts with No-Carrier-Added [18F]Fluoride. Journal of the American Chemical Society, 2007, 129, 8018-8025.	13.7	194
7	Assessment of Treatment Response in Patients with Glioblastoma Using <i>O</i> -(2- <sup>18</sup> F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI. Journal of Nuclear Medicine, 2012, 53, 1048-1057.	5.0	184
8	Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nuclear Medicine and Biology, 2009, 36, 779-787.	0.6	177
9	Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. Journal of Nuclear Medicine, 2007, 48, 519-527.	5.0	171
10	Role of <i>O</i> -(2- <sup>18</sup> F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. Journal of Nuclear Medicine, 2012, 53, 1367-1374.	5.0	171
11	Sleep Deprivation Increases A1 Adenosine Receptor Binding in the Human Brain: A Positron Emission Tomography Study. Journal of Neuroscience, 2007, 27, 2410-2415.	3.6	169
12	Diagnostic Performance of <sup>18</sup> F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma. Journal of Nuclear Medicine, 2013, 54, 229-235.	5.0	167
13	Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight. Nuclear Medicine and Biology, 2017, 55, v-xi.	0.6	162
14	Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 22-33.	6.4	158
15	Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nuclear Medicine and Biology, 2003, 30, 501-508.	0.6	139
16	Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2011, 80, 176-184.	0.8	132
17	Comparison of Cerebral Blood Flow Acquired by Simultaneous [ <sup>15</sup> O]Water Positron Emission Tomography and Arterial Spin Labeling Magnetic Resonance Imaging. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1373-1380.	4.3	118
18	Comparison of <sup>18</sup> F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors. Journal of Nuclear Medicine, 2014, 55, 540-545.	5.0	115

#	Article	IF	Citations
19	Role of $\langle i \rangle O \langle  i \rangle - (2 - \langle \sup) 18 \langle  sup \rangle$ F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. Journal of Nuclear Medicine, 2013, 54, 2046-2054.	5.0	108
20	Preparation of N.C.A. [17-18F]-fluoroheptadecanoic acid in high yields via aminopolyether supported, nucleophilic fluorination. Journal of Labelled Compounds and Radiopharmaceuticals, 1986, 23, 455-466.	1.0	101
21	Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 519-524.	6.4	97
22	Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. Psychoneuroendocrinology, 2014, 39, 74-87.	2.7	86
23	In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. Neurolmage, 2003, 19, 1760-1769.	4.2	84
24	Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiotherapy and Oncology, 2011, 99, 218-224.	0.6	82
25	Fluoroacylation agents based on small n.c.a. [18F]fluorocarboxylic acids. Applied Radiation and Isotopes, 1994, 45, 715-727.	1.5	80
26	Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2144-2151.	6.4	78
27	Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX):Â A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging. Journal of Medicinal Chemistry, 2002, 45, 5150-5156.	6.4	76
28	PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. Journal of Nuclear Medicine, 2005, 46, 411-6.	5.0	75
29	Positron emission intensities in the decay of 64Cu, 76Br and 124l. Radiochimica Acta, 2007, 95, 67-73.	1.2	74
30	lodonium ylides for one-step, no-carrier-added radiofluorination of electron rich arenes, exemplified with 4-(([18F]fluorophenoxy)-phenylmethyl)piperidine NET and SERT ligands. RSC Advances, 2014, 4, 17293-17299.	3.6	70
31	3-[123I]lodo-α-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nuclear Medicine and Biology, 2002, 29, 625-631.	0.6	69
32	18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. Journal of Nuclear Medicine, 2006, 47, 256-61.	5.0	67
33	Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. Journal of Nuclear Medicine, 2004, 45, 374-81.	5.0	65
34	The Usefulness of Dynamic <i>O</i> -(2- <sup>18</sup> F-Fluoroethyl)-l-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents. Journal of Nuclear Medicine, 2015, 56, 88-92.	5.0	64
35	Three-Step, "One-Pot―Radiosynthesis of 6-Fluoro-3,4-Dihydroxy-l-Phenylalanine by Isotopic Exchange. Journal of Nuclear Medicine, 2009, 50, 1724-1729.	5.0	63
36	Excitation function of the $18O(p,n)18F$ nuclear reaction from threshold up to 30 MeV. Radiochimica Acta, 2001, 89, .	1.2	61

3

#	Article	IF	Citations
37	Comparison of pathways to the versatile synthon of no-carrier-added 1-bromo-4-[18F]fluorobenzene. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 429-441.	1.0	60
38	Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. Nuclear Medicine and Biology, 2006, 33, 1029-1035.	0.6	55
39	Multimodal Imaging of Neural Progenitor Cell Fate in Rodents. Molecular Imaging, 2008, 7, 7290.2008.0010.	1.4	49
40	Circadian variation of metabotropic glutamate receptor 5 availability in the rat brain. Journal of Sleep Research, 2016, 25, 754-761.	3.2	47
41	The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Physics in Medicine and Biology, 2009, 54, 5525-5539.	3.0	46
42	Preferred stereoselective brain uptake of d-serine â€" a modulator of glutamatergic neurotransmission. Nuclear Medicine and Biology, 2005, 32, 793-797.	0.6	44
43	Preparation of N.C.A. [18F]-CH2BrF via aminopolyether supported nucleophilic substitution. Journal of Labelled Compounds and Radiopharmaceuticals, 1986, 23, 587-595.	1.0	40
44	Enhanced production possibility of the therapeutic radionuclides 64Cu, 67Cu and 89Sr via (n,p) reactions induced by fast spectral neutrons. Radiochimica Acta, 2004, 92, 183-186.	1.2	40
45	Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anatomy and Embryology, 2005, 210, 519-523.	1.5	39
46	Methods for <sup>11</sup> C―and <sup>18</sup> Fâ€labelling of amino acids and derivatives for positron emission tomography imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 225-236.	1.0	39
47	18F-labelling innovations and their potential for clinical application. Clinical and Translational Imaging, 2018, 6, 169-193.	2.1	37
48	Preferred Stereoselective Transport of the D-isomer of cis-4-[18F]fluoro-proline at the Blood–Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 607-616.	4.3	36
49	Novel CDTA-based, Bifunctional Chelators for Stable and Inert Mn <sup>II</sup> Complexation: Synthesis and Physicochemical Characterization. Inorganic Chemistry, 2017, 56, 7746-7760.	4.0	36
50	Regiospecific no-carrier-added radiobromination and radioiodination of aryltrimethyl Group IVb organometallics. Journal of the Chemical Society Perkin Transactions 1, 1985, , 1941.	0.9	34
51	3-[123I]lodo-α-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 855-861.	2.1	33
52	Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 323-333.	4.3	33
53	Synthesis andÂevaluation ofÂ7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines asÂpotential A2A adenosine receptor antagonists forÂpositron emission tomography (PET). European Journal of Medicinal Chemistry, 2006, 41, 7-15.	5.5	33
54	Comparison of <i>O</i> -(2- <sup>18</sup> F-Fluoroethyl)-l-Tyrosine and l- <sup>3</sup> H-Methionine Uptake in Cerebral Hematomas. Journal of Nuclear Medicine, 2010, 51, 790-797.	5.0	33

#	Article	IF	Citations
55	18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. Journal of Nuclear Medicine, 2005, 46, 450-4.	5.0	32
56	Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology. Nuclear Medicine and Biology, 2021, 92, 78-84.	0.6	30
57	Experimental measurements and nuclear model calculations on the excitation functions of natCe(3He,) Tj ETQq1 140Nd. Radiochimica Acta, 2005, 93, 553-560.	1 0.7843 1.2	14 rgBT /Ove 29
58	4- 18 F]fluoroarylalkylethers via an improved synthesis of n.c.a. 4- 18 F]fluorophenol. Nuclear Medicine and Biology, 2002, 29, 255-262.	0.6	28
59	METABOLISM OF THE A1 ADENOSINE RECEPTOR POSITRON EMISSION TOMOGRAPHY LIGAND [18F]8-CYCLOPENTYL-3-(3-FLUOROPROPYL)-1-PROPYLXANTHINE ([18F]CPFPX) IN RODENTS AND HUMANS. Drug Metabolism and Disposition, 2006, 34, 570-576.	3 <b>.</b> 3	28
60	Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 589-597.	6.4	28
61	Effects of Magnetic Fields of up to 9.4 T on Resolution and Contrast of PET Images as Measured with an MR-BrainPET. PLoS ONE, 2014, 9, e95250.	2.5	28
62	Evaluation of 18F-Labeled Benzodioxine Piperazine-Based Dopamine D4Receptor Ligands: Lipophilicity as a Determinate of Nonspecific Binding. Journal of Medicinal Chemistry, 2011, 54, 8343-8352.	6.4	26
63	Transport of cis- and trans-4-[18F]fluoro-L-proline in F98 glioma cells. Nuclear Medicine and Biology, 2002, 29, 685-692.	0.6	25
64	Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. Neurolmage, 2005, 24, 1192-1204.	4.2	25
65	Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. Journal of Nuclear Medicine, 2003, 44, 1682-9.	5.0	25
66	Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. Nuclear Medicine and Biology, 2013, 40, 795-800.	0.6	24
67	Uptake and tracer kinetics of O-(2-18F-fluoroethyl)-l-tyrosine in meningiomas: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 459-467.	6.4	24
68	Synthesis, radiofluorination and first evaluation of (±)â€{ <sup>18</sup> F]MDL 100907 as serotonin 5â€HT <sub>2A</sub> receptor antagonist for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 6-12.	1.0	23
69	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Annals of Nuclear Medicine, 2018, 32, 236-238.	2.2	23
70	Whole-body kinetics and dosimetry ofl-3-[123I]iodo-?-methyltyrosine. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1162-1166.	2.1	22
71	Radiolabelling with isotopic mixtures of sup>52g/55 (sup>Mn(scp>ii) as a straight route to stable manganese complexes for bimodal PET/MR imaging. Dalton Transactions, 2016, 45, 1315-1321.	3.3	22
72	Enantiospecific synthesis of 2-[18F]fluoro-l-phenylalanine and 2-[18F]fluoro-l-tyrosine by isotopic exchange. Organic and Biomolecular Chemistry, 2011, 9, 765-769.	2.8	21

#	Article	IF	CITATIONS
73	4-[18F]Fluorophenylpiperazines by Improved Hartwig-Buchwald N-Arylation of 4-[18F]fluoroiodobenzene, Formed via Hypervalent l»3-lodane Precursors: Application to Build-Up of the Dopamine D4 Ligand [18F]FAUC 316. Molecules, 2015, 20, 470-486.	3.8	21
74	Direct Nucleophilic 18F-Fluorination of Electron Rich Arenes: Present Limits of No-Carrier-Added Reactions. Current Radiopharmaceuticals, 2010, 3, 163-173.	0.8	21
75	Nuclear data for production of 88Y, 140Nd, 153Sm and 169Yb via novel routes. Radiochimica Acta, 2007, 95, 313-317.	1.2	20
76	Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4-18F-Fluoro-D-Proline. Journal of Nuclear Medicine, 2007, 48, 1482-1491.	5.0	19
77	Carrierâ€effect on palladiumâ€catalyzed, nucleophilic <sup>18</sup> Fâ€fluorination of aryl triflates. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 450-453.	1.0	19
78	Monitoring of Radiochemotherapy in Patients with Glioblastoma Using <i>O</i> -(2-[ <sup>18</sup> ) Tj ETQqC Imaging, 2013, 12, 7290.2013.00056.	0 0 0 rgBT 1.4	Overlock 10 <sup>-</sup> 19
79	Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18. Nuclear Medicine and Biology, 2021, 92, 241-269.	0.6	19
80	Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET. Nuclear Medicine and Biology, 1995, 22, 475-481.	0.6	18
81	Whole-body kinetics and dosimetry of cis-4-[18F]fluoro-l-proline. Nuclear Medicine and Biology, 2001, 28, 287-292.	0.6	18
82	Synthesis, labelling and first evaluation of [ <sup>18</sup> F]R91150 as a serotonin 5â€HT <sub>2A</sub> receptor antagonist for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 13-22.	1.0	18
83	Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-18F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. Nuclear Medicine Communications, 2014, 35, 245-251.	1.1	18
84	Imaging of gliomas with Cis-4-[18F]fluoro-L-proline. Nuclear Medicine and Biology, 2004, 31, 67-75.	0.6	17
85	New cross section measurements for production of the positron emitters 75Br and 76Br via intermediate energy proton induced reactions. Radiochimica Acta, 2009, 97, .	1.2	17
86	Synthesis of No-Carrier-Added 4-[18F]Fluorophenol from 4-Benzyloxyphenyl-(2-thienyl)iodonium Bromide. Molecules, 2011, 16, 7621-7626.	3.8	17
87	Optimized separation procedure for production of no-carrier-added radiomanganese for positron emission tomography. Radiochimica Acta, 2015, 103, 893-899.	1.2	16
88	No-Carrier-Added [18F]Fluorobenzene Derivatives as Intermediates for Built-up Radiosyntheses. Current Radiopharmaceuticals, 2010, 3, 127-160.	0.8	16
89	Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1115-1123.	6.4	15
90	Nucleophilic 18F-Fluorination of Complex Molecules in Activated Carbocyclic Aromatic Position. Current Radiopharmaceuticals, 2010, 3, 109-126.	0.8	15

#	Article	IF	CITATIONS
91	New cross section measurements for the production of the Auger electron emitters <sup>77</sup> Br and <sup>80m</sup> Br. Radiochimica Acta, 2010, 98, 749-755.	1.2	14
92	Bis(4-benzyloxyphenyl)iodonium salts as effective precursors for the no-carrier-added radiosynthesis of 4-[18F]fluorophenol. Applied Radiation and Isotopes, 2013, 82, 264-267.	1.5	14
93	Radiosynthesis of 4-[ 18 F]fluoro- I -tryptophan by isotopic exchange on carbonyl-activated precursors. Bioorganic and Medicinal Chemistry, 2015, 23, 5856-5869.	3.0	14
94	3-[123I]iodo-α-methyl-l-tyrosine transport and 4F2 antigen expression in human glioma cells. Nuclear Medicine and Biology, 2001, 28, 5-11.	0.6	12
95	Alternative syntheses of [73,75Se]selenoethers exemplified for homocysteine [73,75Se]selenolactone. Radiochimica Acta, 2001, 89, 863-866.	1.2	12
96	Application of n.c.a. 4-[18F]fluorophenol in diaryl ether syntheses of 2-(4-[18F]fluorophenoxy)-benzylamines. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 443-455.	1.0	12
97	New potent A1 adenosine receptor radioligands for positron emission tomography. Nuclear Medicine and Biology, 2017, 44, 69-77.	0.6	12
98	Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2′-Fl8)fluoroethylspiperone and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 158-163.	2.1	11
99	Excitation functions of deuteron induced nuclear reactions on enriched 78Kr with particular relevance to the production of 76Br. Radiochimica Acta, 2004, 92, 203-207.	1.2	11
100	4-[18F]fluorophenyl ureas via carbamate-4-nitrophenyl esters and 4-[18F]fluoroaniline. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1037-1050.	1.0	11
101	Convenient preparation of (4-iodophenyl) aryliodonium salts. Tetrahedron, 2012, 68, 4112-4116.	1.9	11
102	PET imaging of pulmonary fibrosis. Journal of Nuclear Medicine, 2003, 44, 483-4; author reply 484.	5.0	11
103	Reactivity of iodine monofluoride on sub-micromolar scale with arenes. Tetrahedron Letters, 1994, 35, 9701-9702.	1.4	10
104	Small scale production of high purity 193mPt by the 192Os(α,ߙ3n)-process. Radiochimica Acta, 2011, 99, 131-135.	1.2	10
105	Production of the positron emitter $51  \text{Mn}$ via the $50  \text{Cr}(d, n)$ reaction: targetry and separation of no-carrier-added radiomanganese. Radiochimica Acta, 2002, 90, 167-177.	1.2	9
106	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 7.	3.9	9
107	First no-carrier-added radioselenation of an adenosine-A1 receptor ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 415-427.	1.0	8
108	Cross Section Measurements on Gas Targets Relevant to the Production of the Positron Emitting Radionuclides140,18F and76Br. Journal of Nuclear Science and Technology, 2002, 39, 1278-1281.	1.3	7

7

#	Article	IF	CITATIONS
109	N-2-(4-N-(4-[18F]Fluorobenzamido)phenyl)-propyl-2-propanesulphonamide: synthesis and radiofluorination of a putative AMPA receptor ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 1169-1175.	1.0	7
110	cis-4-[18F]-Fluoro-l-proline fails to detect peripheral tumors in humans. Nuclear Medicine and Biology, 2008, 35, 895-900.	0.6	7
111	Labeling of benzodioxin piperazines with fluorineâ€18 as prospective radioligands for selective imaging of dopamine D <sub>4</sub> receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 609-618.	1.0	7
112	A threeâ€step radiosynthesis of 6â€{ <sup>18</sup> F]fluoroâ€ <i>Lâ€meta</i> â€tyrosine starting with [ <sup>18</sup> F]fluoride. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 133-140.	1.0	7
113	Stereoselective radiosynthesis of l- and d-3-[18F]fluoro-α-methyltyrosine. Journal of Fluorine Chemistry, 2015, 178, 202-207.	1.7	7
114	Cross section measurements of $\sup 75 \le \int $	1.2	7
115	Status of the â€~consensus nomenclature rules in radiopharmaceutical sciences' initiative. Nuclear Medicine and Biology, 2019, 71, 19-22.	0.6	7
116	Treatment-Related Uptake of $\langle i \rangle O \langle  i \rangle - (2 - \langle \sup \rangle 18 \langle  \sup \rangle F$ -Fluoroethyl)-l-Tyrosine and l-[Methyl- $\langle \sup \rangle 3 \langle  \sup \rangle H$ ]-Methionine After Tumor Resection in Rat Glioma Models. Journal of Nuclear Medicine, 2019, 60, 1373-1379.	5.0	7
117	Efficient synthesis of [ <sup>18</sup> F]FPyME: A new approach for the preparation of maleimideâ€containing prosthetic groups for the conjugation with thiols. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 87-92.	1.0	6
118	<sup>52g/55</sup> Mn-Labelled CDTA-based trimeric complexes as novel bimodal PET/MR probes with high relaxivity. Dalton Transactions, 2019, 48, 3003-3008.	3.3	6
119	New 2α-tropane amides as potential PET ligands for the dopamine transporter. Nuclear Medicine and Biology, 2007, 34, 531-539.	0.6	5
120	[18F]Fluorophenyl organometallics as intermediates of no-carrier-added 18F-fluoroarylation reactions. Journal of Organometallic Chemistry, 2007, 692, 4084-4092.	1.8	5
121	Optimizing the transfer of [18F]fluoride from aqueous to organic solvents by electrodeposition using carbon electrodes. Applied Radiation and Isotopes, 2014, 91, 1-7.	1.5	5
122	11C-labelling of the analgesic tramadol and its major metabolites by selective O- and N-methylation. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1992, 43, 1129-1137.	0.5	4
123	No-carrier-added synthesis of aliphatic and aromatic radioselenoethers via selenocyanates. Nuclear Medicine and Biology, 2003, 30, 361-367.	0.6	4
124	Efficient synthesis of fluorobenzyloxoimidazolidinone derivatives: precursors for the radiosynthesis of [18F]fluorophenylamino acids. Tetrahedron, 2010, 66, 9996-10001.	1.9	4
125	Synthesis, radiofluorination and first evaluation of [18F]fluorophenylsulfonyl- and [18F]fluorophenylsulfinyl-piperidines as serotonin 5-HT2A receptor antagonists for PET. Nuclear Medicine and Biology, 2010, 37, 605-614.	0.6	4
126	Radiochemical separation of 76,77Br and 66,67Ga from irradiated ZnSe targets using anion-exchange chromatography. Radiochimica Acta, 2012, 100, 785-792.	1.2	4

#	Article	IF	CITATIONS
127	Noâ€carrierâ€added labeling of the neuroprotective Ebselen with seleniumâ€₹3 and seleniumâ€₹5. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 141-145.	1.0	4
128	Cis-4-[18F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism. Nuclear Medicine Communications, 2019, 40, 383-387.	1.1	4
129	New modular delivery system for diagnostic and therapeutic pre-targeting using tautomer-specific monoclonal antibody EM-6-47 and 3-substituted adenines., 1998, 77, 610-619.		3
130	Authentically radiolabelled Mn(II) complexes as bimodal PET/MR tracers. EJNMMI Physics, 2015, 2, A85.	2.7	3
131	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Clinical and Translational Imaging, 2019, 7, 61-63.	2.1	3
132	Direct n.c.a. radioiodination of weakly activated arenes using metal salts. Radiochimica Acta, 2000, 88, 221-228.	1.2	2
133	Histogram analysis reveals a better delineation of tumor volume from background in 18F-FET PET compared to CBV maps in a hybrid PET–MR studie in gliomas. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2014, 734. 175-178.	1.6	2
134	Baeyerâ€Villiger oxidation tuned to chemoselective conversion of nonâ€activated [ <sup>18</sup> F]fluorobenzaldehydes to [ <sup>18</sup> F]fluorophenols. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 380-392.	1.0	2
135	Image derived input function applied in CBF Studies with [150]water PET in an integrated MR-PET. EJNMMI Physics, 2014, 1, A30.	2.7	1
136	In Memoriam Gerhard L. Stöcklin. Radiochimica Acta, 2004, 92, 189-191.	1.2	0
137	Obituary of Prof. Stöcklin, Sydney, August 10, 2003. Nuclear Medicine and Biology, 2004, 31, 531.	0.6	O